Skip to main content
SpringerLink
Log in

Is risk-stratified breast cancer screening a better option?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pashayan N, et al. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer. A Life-Table Model. JAMA Oncology : 5 Jul 2018. Available from: URL: http://dx.doi.org/10.1001/jamaoncol.2018.1901.

  2. Roberts MC. Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine. JAMA Oncology : 5 Jul 2018. Available from: URL: http://dx.doi.org/10.1001/jamaoncol.2018.1940.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Is risk-stratified breast cancer screening a better option?. PharmacoEcon Outcomes News 807, 19 (2018). https://doi.org/10.1007/s40274-018-5098-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5098-5

Search

Navigation